Reflections on 10 years of the FDA's breakthrough therapy designation

被引：1
|
作者：
Mullard, Asher
机构：
来源：
NATURE REVIEWS DRUG DISCOVERY | 2022年 / 21卷 / 04期
关键词：
D O I：
10.1038/d41573-022-00053-x
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Ellen Sigal, the founder of Friends of Cancer Research, discusses the origins and future of the FDA's breakthrough therapy designation as well as the changing patient advocacy landscape. Ellen Sigal, the founder of Friends of Cancer Research, discusses the origins and future of the FDA's breakthrough therapy designation as well as the changing patient advocacy landscape.
引用
收藏
页码：252 / 253
页数：2
相关论文
共 50 条
  • [1] Reflections on 10 years of the FDA’s breakthrough therapy designation
    Asher Mullard
    [J]. Nature Reviews Drug Discovery, 2022, 21 : 252 - 253
  • [2] Physician Perceptions of the FDA's Breakthrough Therapy Designation: An Update
    Paquin, Ryan S.
    Boudewyns, Vanessa
    O'Donoghue, Amie C.
    Aikin, Kathryn J.
    [J]. ONCOLOGIST, 2022, 27 (01): : E85 - E88
  • [3] Breakthrough-Therapy Designation - An FDA Perspective
    Corrigan-Curay, Jacqueline
    Mckee, Amy E.
    Stein, Peter
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (15): : 1457 - 1458
  • [4] Rapastinel receives FDA breakthrough therapy designation
    不详
    [J]. NURSE PRACTITIONER, 2016, 41 (04): : 56 - 56
  • [5] Expediting Drug Development - The FDA's New "Breakthrough Therapy" Designation
    Sherman, Rachel E.
    Li, Jun
    Shapley, Stephanie
    Robb, Melissa
    Woodcock, Janet
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (20): : 1877 - 1880
  • [6] The FDA Breakthrough-Drug Designation - Four Years of Experience
    Darrow, Jonathan J.
    Avorn, Jerry
    Kesselheim, Aaron S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (15): : 1444 - 1453
  • [7] FDA Grants Breakthrough Therapy Designation to Magrolimab for MDS Treatment
    不详
    [J]. ONCOLOGY-NEW YORK, 2020, 34 (10): : 430 - 430
  • [8] Breakthrough therapy: FDA's new designation for accelerating approval of promising pipeline therapies
    Calabrese, David
    [J]. FORMULARY, 2013, 48 (08) : 275 - 276
  • [9] IS FDA'S BREAKTHROUGH THERAPY DESIGNATION A GAME-CHANGING TREND FOR PATIENTS AND PAYERS?
    Aggarwal, S.
    Topaloglu, H.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A10 - A10
  • [10] FDA Grants Breakthrough Therapy Designation to Tiragolumab Atezolizumab Therapy for Metastatic NSCLC
    Slater, Hannah
    [J]. ONCOLOGY-NEW YORK, 2021, 35 (02): : 76 - 76
12345